NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment

Durham-based Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).

The study at 10 sites in India will evaluate the safety and efficacy of Biomarck’s novel, patented protein inhibitor, a peptide denoted as BIO-11006, the company said in a news release. The study will compare standard of care therapy — a combination of the chemotherapy drugs pemetrexed and carboplatin — to standard of care plus BIO-11006.